EP3752200A1 — Targeting minimal residual disease in cancer with rxr antagonists
Assigned to Katholieke Universiteit Leuven · Expires 2020-12-23 · 5y expired
What this patent protects
The invention relates to the field of tumor treatment, in particular to melanoma tumor treatment. In particular it relates to the use of retinoid X receptor antagonists for use in tumor treatment, in particular for use in reducing tumor cell heterogeneity during minimal residual …
USPTO Abstract
The invention relates to the field of tumor treatment, in particular to melanoma tumor treatment. In particular it relates to the use of retinoid X receptor antagonists for use in tumor treatment, in particular for use in reducing tumor cell heterogeneity during minimal residual disease (MRD), and thus for use in treating MRD. Even more in particular, the invention relates to the use of retinoid X receptor antagonists in combination with clinically established treatments such as treatment with a combination of BRAF and MEK inhibitors, and optionally other anticancer agents.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.